| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5874447 | SEBELA IRELAND LTD | 4-Phenylpiperidine compounds for treating depression |
Jun, 2017
(6 years ago) | |
| US7598271 | SEBELA IRELAND LTD | Crystalline paroxetine methane sulfonate |
May, 2025
(1 year, 8 days from now) | |
| US8946251 | SEBELA IRELAND LTD | Method of treating thermoregulatory dysfunction with paroxetine |
Aug, 2026
(2 years from now) | |
| US8658663 | SEBELA IRELAND LTD | Method of treating thermoregulatory disfunction with paroxetine |
Apr, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9393237 | SEBELA IRELAND LTD | Method of treating thermoregulatory dysfunction with paroxetine |
Aug, 2026
(2 years from now) | |
Brisdelle is owned by Sebela Ireland Ltd.
Brisdelle contains Paroxetine Mesylate.
Brisdelle has a total of 5 drug patents out of which 1 drug patent has expired.
Expired drug patents of Brisdelle are:
- US5874447
Brisdelle was authorised for market use on 28 June, 2013.
Brisdelle is available in capsule;oral dosage forms.
Brisdelle can be used as treatment of moderate to severe vasomotor symptoms associated with menopause.
The generics of Brisdelle are possible to be released after 06 April, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 28, 2016 |
Drugs and Companies using PAROXETINE MESYLATE ingredient
Market Authorisation Date: 28 June, 2013
Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause
Dosage: CAPSULE;ORAL
BRISDELLE family patents
